Phil is a director in the UK health outcomes team at GSK, overseeing UK HTA submissions throughout the product pipeline. In his role, he has been involved in the UK access strategy for the anti-infectives portfolio, working both internally and with the ABPI industry group to review and contribute to the proposed UK antimicrobial subscription model through the public consultation process.

Prior to joining GSK, Phil was a health economist at the HEOR consultancy Lumanity, with involvement in the development of UK HTA appraisals across various disease areas. Before that, he served as a research fellow for the external assessment group at the University of York, where he reviewed a range of NICE technology appraisal submissions.